These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://brianrhff304629.like-blogs.com/38944746/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide